EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase III)Open Access

Lenvatinib Plus Pembrolizumab Versus Sunitinib in First-Line Treatment of Advanced Renal Cell Carcinoma: Final Prespecified Overall Survival Analysis of CLEAR, a Phase III Study

Robert J Motzer iD, Camillo Porta, Masatoshi Eto, Thomas Powles iD, Viktor Grünwald iD, Thomas E Hutson iD, Boris Alekseev, Sun Young Rha iD, Jaime Merchan iD, Jeffrey C Goh iD, Aly-Khan A Lalani iD, Ugo De Giorgi iD und 25 weitere

Journal of Clinical Oncology · 10.04.2024 · 42 (11) · 1222-1228

DOI: 10.1200/jco.23.01569 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Journal of Clinical Oncology, erschienen am 10.04.2024. Verfasst von Robert J Motzer und 36 weiteren Autor:innen. Beteiligte Einrichtung: Memorial Sloan Kettering Cancer Center, New York, NY. Hauptthemen laut MEDLINE: Carcinoma, Renal Cell, Kidney Neoplasms, Phenylurea Compounds, Quinolines. Die Arbeit wurde bisher 203-mal zitiert (Crossref) und nennt 8 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co-primary or secondary analyses are not yet available. Clinical trial updates provide an opportunity to disseminate additional results from studies, published in JCO or elsewhere, for which the primary end point has already been reported. We present the final prespecified overall survival (OS) analysis of the open-label, phase III CLEAR study in treatment-naïve patients with advanced renal cell carcinoma (aRCC). With an additional follow-up of 23 months from the primary analysis, we report results from the lenvatinib plus pembrolizumab versus sunitinib comparison of CLEAR. Treatment-naïve patients with aRCC were randomly assigned to receive lenvatinib (20 mg orally once daily in 21-day cycles) plus pembrolizumab (200 mg intravenously once every 3 weeks) or sunitinib (50 mg orally once daily [4 weeks on/2 weeks off]). At this data cutoff date (July 31, 2022), the OS hazard ratio (HR) was 0.79 (95% CI, 0.63 to 0.99). The median OS (95% CI) was 53.7 months (95% CI, 48.7 to not estimable [NE]) with lenvatinib plus pembrolizumab versus 54.3 months (95% CI, 40.9 to NE) with sunitinib; 36-month OS rates (95% CI) were 66.4% (95% CI, 61.1 to 71.2) and 60.2% (95% CI, 54.6 to 65.2), respectively. The median progression-free survival (95% CI) was 23.9 months (95% CI, 20.8 to 27.7) with lenvatinib plus pembrolizumab and 9.2 months (95% CI, 6.0 to 11.0) with sunitinib (HR, 0.47 [95% CI, 0.38 to 0.57]). Objective response rate also favored the combination over sunitinib (71.3% v 36.7%; relative risk 1.94 [95% CI, 1.67 to 2.26]). Treatment-emergent adverse events occurred in >90% of patients who received either treatment. In conclusion, lenvatinib plus pembrolizumab achieved consistent, durable benefit with a manageable safety profile in treatment-naïve patients with aRCC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Renal CellKidney NeoplasmsPhenylurea CompoundsQuinolinesAntibodies, Monoclonal, HumanizedHumansSunitinibAntineoplastic Combined Chemotherapy ProtocolsSurvival Analysis

Substanzen

SunitinibpembrolizumablenvatinibPhenylurea CompoundsQuinolinesAntibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • Memorial Sloan Kettering Cancer Center, New York, NY.
  • University of Bari "A. Moro," Bari, Italy.
  • University of Pavia, Pavia, Italy.
  • Kyushu University, Fukuoka, Japan.
  • The Royal Free NHS Trust, London, United Kingdom.
  • University Hospital Essen, Essen, Germany.

ORCID-Profile: Robert J Motzer, Thomas Powles, Viktor Grünwald, Thomas E Hutson, Sun Young Rha, Jaime Merchan, Jeffrey C Goh, Aly-Khan A Lalani, Ugo De Giorgi, Sung-Hoo Hong, Howard Gurney, María José Méndez-Vidal, Sergei Tjulandin, Teresa Alonso Gordoa, Eric Winquist, Miso Kim, Giuseppe Procopio, Jens Bedke, Chinyere E Okpara, Jodi McKenzie, Toni K Choueiri

Förderung

  • NCI NIH HHS

Zitieren

APA

Motzer, R. J., Porta, C., Eto, M., Powles, T., Grünwald, V., Hutson, T. E., Alekseev, B., Rha, S. Y., Merchan, J., Goh, J. C., Lalani, A. A., De Giorgi, U., Melichar, B., Hong, S. H., Gurney, H., Méndez-Vidal, M. J., Kopyltsov, E., Tjulandin, S., Gordoa, T. A., …, & CLEAR Trial Investigators (2024). Lenvatinib Plus Pembrolizumab Versus Sunitinib in First-Line Treatment of Advanced Renal Cell Carcinoma: Final Prespecified Overall Survival Analysis of CLEAR, a Phase III Study. Journal of Clinical Oncology, 42(11), 1222-1228. https://doi.org/10.1200/jco.23.01569

Vancouver

Motzer RJ, Porta C, Eto M, Powles T, Grünwald V, Hutson TE, et al. Lenvatinib Plus Pembrolizumab Versus Sunitinib in First-Line Treatment of Advanced Renal Cell Carcinoma: Final Prespecified Overall Survival Analysis of CLEAR, a Phase III Study. Journal of Clinical Oncology. 2024;42(11):1222-1228. doi:10.1200/jco.23.01569

BibTeX
@article{Motzer2024,
  author = {Motzer, Robert J and Porta, Camillo and Eto, Masatoshi and Powles, Thomas and Grünwald, Viktor and Hutson, Thomas E and Alekseev, Boris and Rha, Sun Young and Merchan, Jaime and Goh, Jeffrey C and Lalani, Aly-Khan A and De Giorgi, Ugo and Melichar, Bohuslav and Hong, Sung-Hoo and Gurney, Howard and Méndez-Vidal, María José and Kopyltsov, Evgeny and Tjulandin, Sergei and Gordoa, Teresa Alonso and Kozlov, Vadim and Alyasova, Anna and Winquist, Eric and Maroto, Pablo and Kim, Miso and Peer, Avivit and Procopio, Giuseppe and Takagi, Toshio and Wong, Shirley and Bedke, Jens and Schmidinger, Manuela and Rodriguez-Lopez, Karla and Burgents, Joseph and He, Cixin and Okpara, Chinyere E and McKenzie, Jodi and Choueiri, Toni K and CLEAR Trial Investigators, CLEAR Trial Investigators},
  title = {Lenvatinib Plus Pembrolizumab Versus Sunitinib in First-Line Treatment of Advanced Renal Cell Carcinoma: Final Prespecified Overall Survival Analysis of CLEAR, a Phase III Study},
  journal = {Journal of Clinical Oncology},
  year = {2024},
  volume = {42},
  number = {11},
  pages = {1222--1228},
  doi = {10.1200/jco.23.01569}
}
Kostenlos starten →